A study published in Nature Cell Biology in August 2026 reveals that FLT3 inhibitors kill acute myeloid leukemia (AML) cells by triggering ferroptosis, a lipid-peroxidation-driven cell death. Researchers led by Dr. Daisuke Nakada found that mutant FLT3 proteins block ferroptosis by activating GPX4, but FLT3 inhibitors suppress GPX4 to allow cell death. However, resistance can occur via selenoprotein overexpression, and dietary vitamin E may compromise treatment efficacy by suppressing ferroptosis.
Ferroptosis mechanism in FLT3-mutated AML
- ▪Researchers led by Dr. Daisuke Nakada at Baylor College of Medicine discovered that mutant FLT3 proteins in acute myeloid leukemia cells activate the GPX4 protein to prevent ferroptosis.
- ▪A study published in Nature Cell Biology in August 2026 reports that FLT3 inhibitors kill acute myeloid leukemia cells by triggering ferroptosis, a form of cell death caused by oxygen-damaging lipids.
- ▪FLT3 inhibitors prevent the production of selenoproteins, including GPX4, leaving acute myeloid leukemia cells with insufficient GPX4 to prevent lipid peroxidation and cell death.
FLT3-ITD mutation characteristics
- ▪The FLT3-ITD mutation is a common, recurrent gene mutation in acute myeloid leukemia that historically lacked adequate standard minimal residual disease detection methods.
- ▪The FLT3 gene mutation occurs in approximately one-third of newly diagnosed acute myeloid leukemia cases.
- ▪FLT3-ITD mutations represent about 80% of all FLT3 mutations and are associated with an increased risk of relapse and shorter overall survival.
Quizartinib treatment across therapy phases
- ▪Quizartinib, marketed as Vanflyta, is FDA-approved for use with chemotherapy in induction and consolidation, and as maintenance monotherapy for adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia.
- ▪Quizartinib carries a boxed warning for QT prolongation, torsades de pointes, and cardiac arrest, and is only available through a restricted Risk Evaluation and Mitigation Strategy program.
- ▪The phase 3 QuANTUM First trial showed that adding quizartinib to chemotherapy decreased the relative risk of death by 22.4% in newly diagnosed FLT3-ITD positive acute myeloid leukemia patients compared to chemotherapy plus placebo.
MRD testing in FLT3-ITD AML
- ▪Results from the QuANTUM First trial showed that a larger share of patients in composite complete remission had undetectable minimal residual disease in the quizartinib arm than in the placebo arm (12.3% vs 7.0%).
- ▪Minimal residual disease measurements using FLT3-ITD-specific assays demonstrate potential prognostic utility in the clinical management of patients with FLT3-ITD-positive acute myeloid leukemia.
Treatment resistance mechanisms
- ▪Dr. Daisuke Nakada of Baylor College of Medicine noted that resistance to FLT3 inhibitors and patient relapse are common in acute myeloid leukemia treatment, prompting research into alternative cell death pathways.
- ▪Data from acute myeloid leukemia patients revealed that leukemia samples resistant to the FLT3 inhibitor gilteritinib often overexpress genes involved in selenoprotein production.
Dietary vitamin E effects
- ▪Researchers found that dietary vitamin E, which attenuates ferroptosis, can markedly reduce the efficacy of the FLT3 inhibitor gilteritinib in acute myeloid leukemia models.
- ▪The August 2026 study in Nature Cell Biology suggests that a high intake of vitamin E may compromise the efficacy of FLT3 inhibitors by suppressing ferroptosis.
Story comments
Loading comments…